17-7675214-A-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001126115.2(TP53):c.2T>C(p.Met1?) variant causes a start lost change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Consequence
TP53
NM_001126115.2 start_lost
NM_001126115.2 start_lost
Scores
10
6
3
Clinical Significance
Conservation
PhyloP100: 9.32
Genes affected
TP53 (HGNC:11998): (tumor protein p53) This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-7675214-A-G is Pathogenic according to our data. Variant chr17-7675214-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 12357.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TP53 | NM_000546.6 | c.398T>C | p.Met133Thr | missense_variant | 5/11 | ENST00000269305.9 | NP_000537.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TP53 | ENST00000269305.9 | c.398T>C | p.Met133Thr | missense_variant | 5/11 | 1 | NM_000546.6 | ENSP00000269305.4 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Cov.: 35
GnomAD4 exome
Cov.:
35
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Li-Fraumeni syndrome 1 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1999 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jun 18, 2022 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 26, 2023 | The p.M133T pathogenic mutation (also known as c.398T>C), located in coding exon 4 of the TP53 gene, results from a T to C substitution at nucleotide position 398. The methionine at codon 133 is replaced by threonine, an amino acid with some similar properties. This alteration was reported in a large family with Li-Fraumeni syndrome (LFS) and was found to segregate with LFS spectrum tumors in nine affected family members (Law J et al. Cancer Res. 1991 Dec;51:6385-7). In addition, this alteration was detected in a second large pedigree with several LFS tumors, and was found to segregate with disease in three affected family members (Shay J et al. Mol. Cell. Biol. 1995 Jan;15:425-32). This variant is in the DNA binding domain of the TP53 protein and is reported to have loss of transactivation in yeast based assays (IARC TP53 database: Kato S et al. Proc. Natl. Acad. Sci. USA 2003 Jul;100:8424-9). Studies conducted in human cell lines indicate this alteration is deficient at growth suppression (Kotler E et al. Mol. Cell 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). The p.M133T alteration was also shown to have less than 25% binding capacity to multiple response elements when compared to wild type TP53 (Malcikova J et al. Biol. Chem.;391:197-205). Based on internal structural analysis, this variant is anticipated to result in a significant decrease in structural stability (Cho Y et al. Science 1994 Jul; 265(5170):346-55; Ambry internal data). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jun 18, 2022 | - - |
Li-Fraumeni syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 09, 2021 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this variant affects TP53 protein function (PMID: 20128691, 12826609, 21343334, 29979965, 30224644). This variant has been observed in individual(s) with Li-Fraumeni syndrome (PMID: 1933902, 10477429). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 12357). This variant is not present in population databases (ExAC no frequency). This sequence change replaces methionine with threonine at codon 133 of the TP53 protein (p.Met133Thr). The methionine residue is weakly conserved and there is a moderate physicochemical difference between methionine and threonine. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 19, 2022 | Segregates with disease in many affected individuals with LFS-associated cancers from two large families in published literature (Law et al., 1991; Shay et al., 1995; Hung et al., 1999); Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate a damaging effect: impaired DNA binding, lack of transcriptional activation, loss of growth suppression activities, and a dominant-negative effect (Kato et al., 2003; Malcikova et al., 2010; Monti et al., 2011; Jagosova et al., 2012; Giacomelli et al., 2018; Kotler et al., 2018); This variant is associated with the following publications: (PMID: 22507745, 30224644, 17606709, 30840781, 21311097, 21317445, 21305319, 31105275, 22710932, 21343334, 20128691, 12826609, 29979965, 10477429, 1933902, 7799951, 15510160, 34273903) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D;D;.;.;.;.;D;.;.;.;.;.;.;D;.;.;.;D;D;D
Eigen
Benign
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D;D;.;.;.;D;D;.;D;D;D;D;D;D;D;D;T
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
.;.;.;.;.;.;N;.;N;N;N;.;.;N;.;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D;.;.;.;.;D;.;.;D;D;.;.;D;.;.;D;D;D;.
REVEL
Pathogenic
Sift
Pathogenic
D;D;.;.;.;.;D;.;.;D;D;.;.;D;.;.;D;D;D;.
Sift4G
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;.;.;D
Polyphen
P;.;.;.;.;.;B;.;B;B;B;.;.;B;.;.;.;B;.;.
Vest4
MutPred
Loss of catalytic residue at M133 (P = 0.0062);Loss of catalytic residue at M133 (P = 0.0062);.;.;.;.;Loss of catalytic residue at M133 (P = 0.0062);.;Loss of catalytic residue at M133 (P = 0.0062);Loss of catalytic residue at M133 (P = 0.0062);Loss of catalytic residue at M133 (P = 0.0062);.;.;Loss of catalytic residue at M133 (P = 0.0062);.;.;.;.;Loss of catalytic residue at M133 (P = 0.0062);.;
MVP
MPC
0.97
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at